o,p '-dichlorodiphenyldichloroethane (o,p'-ddd, mitotane 
dogenesis in vitroencounteredconsiderabledifficulties. It is known that o,p'-DDD is virtually insoluble inwater(0.1mg/lat25°C;0.3μM),andaddingof o,p'-DDD in powder to the incubation medium in some experiments had no success.
Important results that shed light on the conditions for realization of o,p'-DDD action in vitro were obtained by V. I. Kravchenko [3] . Blood plasma containing a propylene glycol solution of o,p'-DDD was used in the reported work. It was found that at incubation of dog adrenal slices under these conditions, synthesis of corticosteroids from endogenous precursors, as well as from added progesterone did not alter. However, in the experiments with dog adrenal homogenate, a clear decrease in the corticosteroid production was observed [3] . The penetrating of o,p'-DDD into cells might be a very complex process, so the incubation of the slices appears to be not sufficientlyaccuratemethodinstudyingtheactionof o,p'-DDD. A successful attempt to inhibit the corticosteroids secretion by o,p'-DDD was reported in [4] . The authors perfused the dog adrenal glands with a solution of o,p'-DDD in Krebs-Ringer-bicarbonate medium or in blood plasma. It was established that the adrenal cortex did not respond to ACTH, added to the perfused solution, by increased corticosteroid production. Inhibition of steroidogenesis during the incubation of slices in the o,p'-DDD containing medium was not observed.
In dogs treated with o,p'-DDD, a variety of biochemical changes in the cortical tissue and atrophy of the gland cortical layer were observed. Thus, a decrease in the activity of enzymes involved in NADP reduction (a cofactor of hydroxylase reactions of steroidogenesis) was established [5] . NADPH serves as a hydrogen donor for hydroxylation reactionsthe most important reactions of steroidogenesis. It is also a cofactor of glutathione reductase, which is involved in maintaining the necessary level of reduced glutathione in cells. In the adrenal tissue of dogs receiving o,p'-DDD, a considerable decrease in the content of SH-groups was observed [6] . Under these conditions the glutathione reductase activity substantially increased. This increase was observed already 24 h after a single feeding with o,p'-DDD at a dose of 50 mg per kg of animal weight [7] . Such increase in the activity of glutathione reductase might be a compensatory response. In vitro, o,p'-DDD also activated glutathione reductase of the adrenal glands, but not of the kidneys and liver [8] .
It is well known that glutathione is involved in neutralizing peroxides, reactive oxygen species and foreign compounds. The ability to neutralize foreign compounds determines, to a large extent, the drug efficacy and the development of tumor resistance topharmaceuticalagents.Thesefindingsprompted us to study how o,p'-DDD affects glutathione-Stransferase (EC 2.5.1.18) activity in animals who are sensitive or resistant to o,p'-DDD adrenocorticolytic action. Feeding dogs with o,p'-DDD caused a decrease in the enzyme activity in the adrenal glands, but did not change the enzyme activity in the liver. Inhibition of glutathione-S-transferase activity in the adrenal glands of dogs receiving o,p'-DDD may be account for the adrenocorticolytic effect of the drug. In guinea pigs, the enzyme activity increased in both the adrenal glands and the liver [9] . In vitro o,p'-DDD markedly inhibited the activity of glutathione-S-transferase in dog adrenal glands and less marked ly in the adrenals of guinea pigs. In rats receiving o,p'-DDD, the activity of glutathione-S-transferase in the adrenal glands also decreased, but increased in the liver [10] . The level of reduced glutathione in these tissues changed in the opposite way -increased in the adrenal glands and decreased in the liver. This is the typical response of liver tissue to xenobiotics.
Since treatment of adrenocortical cancer with o,p'-DDD does not always give positive results, some researchers have tried to find biochemical predictorsofthedrugefficacy.Thus,ribonucleotide reductase (EC 1.17.4.1) was considered as such a predictor [11] . This enzyme catalyzes the synthesis of deoxyribonucleotides essential for DNA synthesis. The enzyme contains two subunits encoded by different genes. The pronounced expression of RRM1 gene in patients is associated with shortening of remission and life expectancy. Thus, in patients with low level of RRM1 expression, mitotane treatment prolonged the remission period. In patients with high level of RRM1expressionsucheffectwasnot observed. In vitro,mitotanecausedasignificantincrease in RRM1 transcription in SW13 cells, which are resistant to mitotane, but not in mitotane susceptible H295R cells. Moreover, the suppression of RRM1byspecificmicroRNAssensitizedSW13cells to mitotane. The authors suggested that RRM1 may serve as a biomarker enabling to predict the tumor response to mitotane treatment. A deeper analysis of biomarkers for adrenocortical cancer sensitivity/ resistance to drugs was reported in [12] . The results showed that mitotane and cisplatin are effective in treatment of patients with low level of proteins RRM1 and ERCC1 (DNA excision repair protein). CYP2W1 was also considered as a biomarker [13] . The authors found that CYP2W1 expression was high in the majority of adrenal tumors both benign and malignant. Moreover, the level of immunoreactive CYP2W1 in tumors is associated with hormoneactivity,amoredifferentiatedphenotype,and in cancer, with a better response to mitotane treatment. These findings allow considering CYP2W1 as a possible marker to prognose tumor response to mitotane used as an adjuvant or palliative therapy aftersurgery.TheactivityoftopoisomeraseIIαand thymidylate synthase as prognostic criteria was analyzed in [14] . The activity of these enzymes in tumor tissuewasfoundnottobeassociatedwiththeeffect of mitotane.
Metabolism of o,p'-DDD incubated with dog adrenal mitochondria, microsomes and cytosol was studied [15] . In the presence of NADPH and system of its reduction, mitochondria converted o,p'-DDD intofivedifferentcompounds,amongwhicho,p'-dichlorodiphenylacetic acid was identified. The metabo lism was sharply inhibited when the incubation was carried out in a CO atmosphere, or in the absence of NADPH in the medium. o,p'-DDD was not metabolized in cytosol and microsome fractions. The authors suggested that the ability of metabolites to covalently bind to mitochondria proteins determines the adrenocorticolytic activity of o,p'-DDD [16] . Incubation of dog adrenal homogenate with 125 I-labeled o,p'-DDD showed that the radioactivity was mainly associated with proteins, and the phospholipid fraction contained about 17% of the total radioactivity [17] . After hydrolysis of the complexes, the only metabolite of o,p'-DDD was found to be chlorophenyl-1-iodophenylacetic acid. After incubation of the dog, bovine and human adrenal homogenates, the bound o,p'-DDD metabolites were separated by electrophoresis [18] . The electrophoregrams were similar for all homogenates. Among the radiolabeled proteins, cytochrome P450 scc was detected by Western blotting. The hypothesis that o,p'-dichlorodiphenylacetic acid (o,p'-DDA) is the active metabolite of o,p'-DDD was tested [19] [19] .
Histologic and electron microscopic changes in the dog adrenal cortex occurring after o,p'-DDD administration were described in a number of research [20] [21] [22] . Electron microscopy analysis demon strated that adrenal mitochondria swelled in 2-4 h after a single administration of o,p'-DDD to dogs. o,p'-DDD wasfoundtoaffectendoplasmicreticulum,tolead to myeloid-like structure formation, as well as an increase in the number and size of autolyso some structures [20, 21] . Analysis of H295R and SW13 adrenocortical cancer cells exposed to o,p'-DDD by electron microscopy revealed dose-and timedependent changes in mitochondria structure [23] . Swelling and disruption of cristae, formation of myelin-like structures on the inner mitochondrial membrane as well as cytoplasmic vacuolization were observed. Increasing of o,p'-DDD concentration led to a decrease in the total number of mitochondria. Mitochondria swelling and degeneration were also observed in the experiments on culture of Fang-8 cells exposed to o,p'-DDD (Fang-8 cells derived from estrogen-producing adrenal tumor and retained steroidogenic activity) [24] . In vitro o,p'-DDD caused a drastic inhibition of mitochondrial respiration in the liver and kidneys of dogs and guinea pigs [25] .
Development of stable culture of adrenal tumor cells played an important role in further research of the mechanism of o,p'-DDD action -many researchers began to use them in the studies. o,p'-DDD(10-40μM)inhibitedbasaland cAMP-activa ted hydrocortisone secretion by H295 cells, but did not cause their death [26] . It inhibited the basal expression of StAR and P450 scc proteins and decreased the expression of mRNA StAR, CYP11A1 and CYP21. It was found that o,p'-DDD hasastimulatoryeffectonCYP11B1.Theaddition of cAMP to control samples elevated the expression of steroi dogenic genes. o,p'-DDD(40μM)almost completely neutrali zed the effect of cAMP. The authors concluded that o,p'-DDD can inhibit corticosteroidbiosynthesisvianon-specificinteraction with transcription of steroidogenic enzymes. Gene expression in H295R cells treated with o,p'-DDD at concentrations that inhibit steroidogenesis butdonotaffectcellviabilitywasstudied [27] .Isolated RNA was further analyzed using microarrays. Comparedtocontrol,differencesintheexpressionof 117 genes were found. Three steroidogenesis regulatory genes hSd3B1, hSd3B2 and CYP21A2 were underexpressed, and four genes GdF15, ALdh1L2, TRIB3 and SERPINE2 were overexpressed. A decrease in the mRNA level of cytochromes CYP11A1 and CYP17A1 in H295R cells in the presence of o,p'-DDD was shown in the study [28] . o,p'-DDD was found to cause a decrease in the level of mRNA protein kinase A regulatory subunit (PRKAR1A). These changes explain the molecular mechanisms of inhibition of steroidogenesis by o,p'-DDD.
Qualitative and quantitative alterations in the mitochondrial morphology and function in H295R and SW13 cells were evaluated in [23] . The accumulation of o,p'-DDD and o,p'-DDE (o,p'-dichlorodiphenyldichloroethylene -metabolite of o,p'-DDD) in H295R cells was found to be dependent on the concentration (directly proportional) in the medium(10-100μM).Thenumberofcellsdecreased proportional ly to concentration and time. Such decreasemayresultfromthecombinedeffectonviability and proliferation. The IC 50 for these parameters ranged from 10 to 20 μM. The toxic effect of o,p'-DDD on SW13 cells was also established. Quantification of apoptosis by annexin V showed that exposure to o,p'-DDDatdosesof30and50μM for 48 h led to an increase in the percentage of apoptotic cells. The level of caspase-3 and -7 increased in the cells. The increased caspase-3 and -7 activities in these cells were also shown by other researchers [28] .Theinfluen ceofo,p'-DDD on apoptotic DNA fragmentation in vitro was analyzed in our work [29] . Western blot analysis showed that o,p'-DDD reduced the expression of the mitochondrial anion channel VDAC in the outer membrane, increased the expressionofcaspase-3butdidnotaffectthelevelofsuc-cinate dehydrogenase (complex II) in the mitochondriainnermembrane [23] .Theeffectofo,p'-DDD on respiratory chain was studied on cultured H295R and SW13 cells derived from human adrenocortical carcinoma [31] . It was shown that o,p'-DDD at a concentration of 50 μM inhibited respiration 2-fold in both cell lines at the stage of complex IV (cytochrome c oxidase). The activity of complex II (succinate-ubiquinone oxidoreductase) remained unchanged. Complex III (ubiquinol-cytochrome c oxidoreductase) was inhibited slightly and only in SW13 cells. The IC 50 for the IV complex was found tobe~67μM.Itisknownthatcytochromeoxidase includes 13 subunits; three of them are encoded by the mitochondrial genome, the rest -by nuclear. Mitochondrial : nuclear subunits ratio in transcripts reduced in H295R cells treated by o,p'-DDD by 70%. Similar results were obtained in experiments with SW13 cells. Protein analysis revealed that exposure for 48 h reduced the level of complexes IV and I by 45-70%, but did not alter the level of complexes II and III [31] .
The above data demonstrate that mitochondria are likely to be the main intracellular target for the o,p'-DDD action. It is mitochondria where the most important reactions of respiration and oxidative phosphorylation as well as steroidogenic reactions occur. Interaction between mitochondria and endoplasmic reticulum (ER) was reported to play an important role in steroidogenesis [32] . This interaction occurs in the specialized contact cites and results in theformationofspecificsubcellulardomainscalled mitochondrial-associated membranes (MAMs). This coupling plays an important role in some cellular processes, in particular, in Ca 2+ transport and apoptosis [33] . Thus, MAMs may be considered as functional adapters of changes in cell homeostasis. It was shown in [34] that FATE1, a cancer-testis antigen, plays an important role in the regulation of the ER -mitochondria distance [34] . FATE1 is expressed in adrenal cancer cells under the control of the transcription factor SF1 and increases the distance between ER and mitochondria, reducing mitochondrial Ca 2+ uptake. FATE1 also decreases sensitivity to proapoptoticeffectsandtoo,p'-DDD [34] .
Steroidogenesis occurs mainly on mitochondrial membranes, the main components of which are cholesterol and phospholipids [35] . The adrenal gland is characterized by a high content of 7,10,13,16-docosatetraenoic acid (a trivial name adrenic acid) in phospholipids. The phospholipid composition of the adrenal glands of humans and dogs is very close and differ only in the sphingomyelin level which was found to be significantly higher in humans [36] . In dogs treated with o,p'-DDD (50 mg/kg) the phospholipid composition of the adrenal cortex was shown to be altered. The level of phosphatidylserine, phosphatidylinositol and sphingomyelin increased, whereas the level of diphosphatidylglycerol and lysophosphatidylethanolamine decreased. Such decrease in the diphosphatidylglyce rol level is associated with the destruction of mitochondria caused by o,p'-DDD [37] . It is known that diphosphatidylglycerol (cardiolipin) is an important constituent of the inner mitochondrial membranes [38] . The formation of a cholesterol complex with cytochrome P450 scc (which cleaves the cholesterol side chain to form pregnenolone) appeared to depend on the phospholipid composition of the medium, and cardiolipin is the most active phospholipid [39] .
A direct interaction of o,p'-DDD with membranes was studied on unilamellar membrane system prepared from cholesterol and phospholipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine) [40] . o,p'-DDD constituted 20 molecular % of phospholipids. It was found that o,p'-DDD and its main metabolite dichlorodiphenylacetic acid (o,p'-DDA) bind to lipid membranes anchoring into the lipid-water interface. o,p'-DDD, but not o,p'-DDA, directly causes a disruption to the bilayer structure leading to increased membrane permeabilityforpolarmolecules.Westudiedtheeffect of o,p'-DDD on the process of mitochondria swelling in vitro [41] . Adding o,p'-DDD to the medium was found to increase dramatically the rate and degree of the adrenal mitochondria swelling. The nature and value of the changes depend on the o,p'-DDD concentration in the conditions of constant concentration of mitochondrial protein. The peculiarity of the o,p'-DDD-induced swelling is the inverse temperature-degree dependence: with increasing temperature, the degree of swelling decreases. These findingsmayindicatethatweakbonds(hydrophobic or Van der Waals) are formed between o,p'-DDD and the mitochondrial lipid components. These bonds readily dissociate as the temperature rises. The sig- [42] .Theauthorsstudiedtheeffectofo,p'-DDD on human erythrocytes in vitro. At the therapeutic doses of o,p'-DDD, phosphatidylserine translocation in erythrocyte membranes from the inner layer into the outer layer occurred. Under these conditions the cellular Ca 2+ level substantially increased, hemolysis was enhanced. In the absence of Ca 2+ , inhibition of translocation of phosphatidylserine, determined by annexin V binding , was observed. Moreover, o,p'-DDD inhibited the Ca 2+ -induced shrinkage of erythrocytes.
In 1994, at the European Congress on Endocrinology, we hypothesized that adrenocorticocyte membranes are the main locus of the o,p'-DDD action. Dissolving in the lipid phase of membranes, it disrupted their organization, and changes in the membrane physico-chemical properties led to the cell damage [43] . The possible sequence of events was suggested to be as follows: 1. Accumulation of o,p'-DDD in membranes. 2. Damage to the membrane functions (ion pumps, electron transport, function of membrane-bound enzymes). 3. Activation of peroxidation processes. 4. Impairment of synthesis and function of macromolecules by products of peroxidation (Fig.) .
Thediscoveredinhibitoryeffectofo,p'-DDD on sterol O-acyltransferase (EC 2.3.1.26), often referred to as ACAT (acyl-CoA cholesterol acyltransferase) or SOAT [44] , has drawn a lot of attention. In adrenal tissue this enzyme converts cholesterol into its esters. There are two isoforms of the enzyme that differindistributionandfunction.SOAT1ispresent in adrenal, kidney and macrophages. Some inhibitors (PD132301-2 (or ATR-101) is the most studied) of this enzyme, developed for treatment of atherosclerosis, induce degeneration of adrenal cortex [45] . Thiseffectwasobservedindogs;howeveritwasnot found in rats and mice. The study of inhibition of ACATsignificantlyimprovedanddeepenedtheunderstanding of the mechanism of o,p'-DDD adrenocorticolytic activity.
In vitro, in H295R cells, ATR-101 induced mitochondria hyperpolarization, increased the ROS formation within 1 h of exposure [46] . ATR-101 treatment of H295R cells led to the accumulation of free fatty acids and cholesterol that induces ER stress [47] . In so doing the increased caspase 3/7 activity and activation of apoptosis, assessed by terminal deoxynucleotidyl transferase nick end labe-
The scheme of mitochondrial processes affected by o,p'-dichlorodiphenyldichloroethane (o,p'-DDD, mitotane, chloditane). A -adrenodoxin, AR -adrenodoxin reductase, Cyt P450 -cytochrome P450 scc , I-IV -mitochondrial respiratory chain enzymes, Q -ubiquinone
ling (TUNEL assay), were observed. ATR-101 also caused the unfolded protein response resulting in ER stress. Treatment of dogs with ATR-101 decreased the formation of corticosteroids and induced adrenocorticocytes apoptosis, followed by a decrease in the adrenal cortex. The authors suggested that the use of ATR-101 (the ACAT inhibitor) may be promising in the treatment of adrenalcortical cancer [47] . In H295 cells, o,p'-DDD dramatically increased the expression of reticular stress marker CHOP (transcription factor encoded by the ddIT3 gene) [44] . o,p'-DDD also activated two preceding stress factors XBP1 andeIF2α.Inadrenalcancercells,theexpression ofACATvariesandthiscandefinetheo,p'-DDD susceptibility of these cells. Since the endoplasmic reticulum stress can be activated by various compounds, the potential synergy between o,p'-DDD and proteasome inhibitors: MG132, bortezomib В огляді наведено дані щодо біохімічного механізму дії о,п'-дихлордифенілдихлоретану (о,п'-ДДД, мітотан), який використовується для лікування раку кори надниркових залоз і хвороби Кушинга. Під впливом препарату виникають численні біохімічні зміни в корі надниркових залоз і порушується структура мітохондрій.Прицьомуістотнознижуєтьсяут-ворення кортикостероїдних гормонів. Однією з можливих причин цього може бути зниження рівняNADPHчерезпригніченняактивностіси-стемйоговідновленняіпідвищеноївитратидля відновлення глутатіону глутатіонредуктазою. У надниркових залозах о,п'-ДДД частково метаболізується і його основним метаболітом є о,п'-дихлордифенілоцтова кислота (з точ-ки зору кількості). Однак спроби знайти серед метаболітівфізіологічноактивнийкомпонентне мали успіху. Найвираженіші зміни, спричинені о,п'-ДДД, знайдено в мітохондріях коркового шару надниркових залоз: пригнічується ди-хання на рівні IV і I комплексів, знижується вміст протеїнів цих комплексів, змінюється фосфоліпіднийскладтканиниізнижуєтьсявміст дифосфатидилгліцеролу -найважливішого компонента мембран мітохондрій. На нашу думку, о,п'-ДДД завдяки високій ліпофільності накопичується в мембранах мітохондрій і зумовлює їх конформаційні порушення з по-дальшимпорушеннямфункції.Встановлено,що о,п'-ДДД є інгібітором ацил-CоА-холестерол-ацилтрансферази (АХАТ, SOAT1). Через це в адренокортикоцитахнакопичуєтьсявільнийхо-лестерол,виникаєстресендоплазматичногоре-тикулума,розвиваєтьсянабуханнямітохондрійі активуютьсякаспази.Посиленняапоптозупри-зводитьдозменшенняфункціїзалозиізнижен-няїїмаси.
К л ю ч о в і с л о в а:коранаднирковихза-лоз,стероїдогенез,мітотан,хлодитан,глутатіон, мітохондрії, стрес ендоплазматичного ретику-лума,апоптоз.
Биохимический механизм действия о,п′-ддд на кору надпочечных желез
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ГУ«Институтэндокринологиииобменавеществ им.В.П.КомиссаренкоНАМНУкраины»,Киев; e-mail: asmikosha@gmail.com В обзоре представлены данные о био-химическом механизме действия о,п'-дихлордифенилдихлорэтана (о,п'-ДДД, мито-тан), который используется для лечения рака коры надпочечников и болезни Кушинга. Под действием препарата возникают многочислен-ныебиохимическиеизменениявкоренадпочеч-ныхжелезинарушаетсяструктурамитохондрий. При этом существенно снижается образование кортикостероидныхгормонов.Однойизвозмож-ныхпричинэтогоможетбытьснижениеуровня NADPHиз-заподавленияактивностисистемего восстановления и повышенного расходования для восстановления глутатиона глутатионре-дуктазой. В надпочечниках о,п'-ДДД частично метаболизируетсяиосновнымегометаболитом является о,п´-дихлордифенилуксусная кислота (с точки зрения количества). Однако попытки найти среди метаболитов физиологически ак-тивныйкомпонентбылибезуспешны.Наиболее выраженные изменения, вызываемые о,п'-ДДД, выявлены в митохондриях коркового вещества надпочечников:подавляетсядыханиенауровне IV и I комплексов, снижается содержание про-теинов этих комплексов, изменяется фосфоли-пидный состав ткани и снижается содержание дифосфатидилглицерола -важнейшего компо-нента мембран митохондрий. По нашему мне-нию, о,п'-ДДД из-за высокой липофильности накапливаетсявмембранахмитохондрийивы-зываетееконформационныенарушенияспосле-дующиминарушениямифункции.Установлено, что о,п'-ДДД является ингибитором ацил-КоА-холестеролацилтрансферазы (АХАТ, SOAT1). Из-за этого в адренокортикоцитах накаплива-ется свободный холестерол, возникает стресс эндоплазматического ретикулума, развивается набуханиемитохондрийиактивируютсякаспа-зы.Усилениеапоптозаприводиткуменьшению функциижелезыиснижениюеемассы.
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